Free Trial
NASDAQ:OVID

Ovid Therapeutics Q4 2024 Earnings Report

Ovid Therapeutics logo
$0.35 +0.01 (+3.00%)
Closing price 04/25/2025 04:00 PM Eastern
Extended Trading
$0.37 +0.02 (+5.79%)
As of 04/25/2025 07:03 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ovid Therapeutics EPS Results

Actual EPS
-$0.13
Consensus EPS
-$0.16
Beat/Miss
Beat by +$0.03
One Year Ago EPS
N/A

Ovid Therapeutics Revenue Results

Actual Revenue
$0.08 million
Expected Revenue
$0.19 million
Beat/Miss
Missed by -$112.00 thousand
YoY Revenue Growth
N/A

Ovid Therapeutics Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Monday, March 10, 2025
Conference Call Time
7:00PM ET

Upcoming Earnings

Ovid Therapeutics' Q1 2025 earnings is scheduled for Tuesday, May 13, 2025, with a conference call scheduled at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Ovid Therapeutics Earnings Headlines

Real Americans Don’t Wait on Wall Street’s Next Move
What's happening in the markets right now should concern every freedom-loving American who's worked hard and saved smart. Your 401(k) doesn't deserve to be dragged through the mud by tariffs, trade wars, reckless spending, and political standoffs. And you don't have to stand by while Wall Street plays roulette with your future.
Ovid Therapeutics (OVID) Receives a Buy from TD Cowen
See More Ovid Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Ovid Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ovid Therapeutics and other key companies, straight to your email.

About Ovid Therapeutics

Ovid Therapeutics (NASDAQ:OVID), a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

View Ovid Therapeutics Profile

More Earnings Resources from MarketBeat